Company Continues to Advance PMA Application for vCLAS Ventricular Ablation System While Board Evaluates Full Range of Strategic Options LAGUNA HILLS, Calif. --(BUSINESS WIRE)--Sep. 23, 2026-- Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter
Enrollment Underway Across Multiple Sites as Study Advances Faster, Improved ULTA Catheter for the Broadest Population of VT Patients LAGUNA HILLS, Calif. --(BUSINESS WIRE)--Sep. 16, 2026-- Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter
LAGUNA HILLS, Calif. --(BUSINESS WIRE)--Aug. 11, 2026-- Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the second quarter ended June 30,
vCLAS Ultra System Designed to Optimize Usability and Workstream to Address Entire Spectrum of Ventricular Tachycardia Patients LAGUNA HILLS, Calif. --(BUSINESS WIRE)--Aug. 3, 2026-- Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation
PMA Submission Supported by FULCRUM-VT Pivotal Trial Data — 209 Patients Across 20 Leading Centers; Breakthrough Device Designation Previously Granted Marks the First-Ever PMA Submission for a Purpose-Built VT Ablation System in a $5.8B Market LAGUNA HILLS, Calif.
Advancing Toward Submission for PMA Approval Following Late-Breaking FULCRUM-VT Data LAGUNA HILLS, Calif. --(BUSINESS WIRE)--May 12, 2026-- Adagio Medical Holdings, Inc (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac
LAGUNA HILLS, Calif. --(BUSINESS WIRE)--Apr. 29, 2026-- Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be presenting at the BofA Securities
84% Freedom From Shock and 59% Freedom From VT Recurrence in FULCRUM-VT Pivotal IDE Trial Meet Safety and Effectiveness Endpoints and Replicate CryoCure-VT Results First and Only Ablation Technology to Show Equivalent Effectiveness Across Ischemic and Non-Ischemic Cardiomyopathy All From
Use of ULTA Across Broad Spectrum of Ventricular Tachycardias to be Highlighted in Multiple Scientific Presentations, Including Late-Breaking Clinical Trial Session LAGUNA HILLS, Calif. --(BUSINESS WIRE)--Apr. 16, 2026-- Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a
Designed to Deliver Faster, More Efficient Ablation with Improved Usability on Established, Titratable, Endocardial-Approach ULTA Platform LAGUNA HILLS, Calif. --(BUSINESS WIRE)--Apr. 8, 2026-- Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter
